Astrazeneca (AZN) EBITDA Margin Growth (1y) (2010 - 2026)
Astrazeneca (AZN) EBITDA Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBITDA Margin Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
57.00 |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
660.00 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-179.00 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-138.00 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-6,345.00 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
1,648.00 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
360.00 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
2,760.00 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
437.00 |
| 10 |
Astrazeneca |
72.15 Bn |
64.21 Bn |
12.61 Bn |
-191,576.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
-191,576.00 |
| Dec 31, 2025 |
4.63 Mn |
| Sep 30, 2025 |
1.89 Mn |
| Jun 30, 2025 |
-381,250.00 |
| Mar 31, 2025 |
152,006.00 |
| Dec 31, 2024 |
-65,622.00 |
| Sep 30, 2024 |
320,715.00 |
| Jun 30, 2024 |
4.75 Mn |
| Mar 31, 2024 |
-416,370.00 |
| Dec 31, 2023 |
-44,158.00 |
| Sep 30, 2023 |
92,210.00 |
| Jun 30, 2023 |
-1.16 Mn |
| Mar 31, 2023 |
792,450.00 |
| Dec 31, 2022 |
122,960.00 |
| Sep 30, 2022 |
196,064.00 |
| Jun 30, 2022 |
1.17 Mn |
| Mar 31, 2022 |
-3,114.00 |
| Dec 31, 2021 |
-63,013.00 |
| Sep 30, 2021 |
-346,239.00 |
| Jun 30, 2021 |
-18,374.00 |
